

CITATION REPORT

List of articles citing

Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study

DOI: 10.1378/chest.10-0969
Chest, 2011, 140, 1274-1283.

Source: <https://exaly.com/paper-pdf/52047743/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
224	Treatment of pulmonary arterial hypertension (PAH): updated Recommendations of the Cologne Consensus Conference 2011. 2011 , 154 Suppl 1, S20-33		38
223	Potential for phosphodiesterase inhibitors in the management of autoimmune diseases. 2011 , 72, 772-778		1
222	Treatment of pulmonary arterial hypertension with targeted therapies. 2011 , 8, 526-38		102
221	Overview of current therapeutic approaches for pulmonary hypertension. 2011 , 1, 138-59		34
220	Medical Treatment of Pulmonary Arterial Hypertension. 2012 , 237-245		
219	Long-term safety and efficacy of ambrisentan in Japanese adults with pulmonary arterial hypertension. 2012 , 28, 1069-76		7
218	Sildenafil therapy for bronchopulmonary dysplasia: not quite yet. 2012 , 32, 1-3		15
217	Early detection and management of pulmonary arterial hypertension. 2012 , 21, 306-12		67
216	PDE5 inhibitor treatment options for urologic and non-urologic indications: 2012 update. 2012 , 18, 5590-606		14
215	How long can we leave patients with pulmonary arterial hypertension on oral drug monotherapy?. 2012 , 76, 1089-90		1
214	Long-term Treatment With Sildenafil Citrate in Pulmonary Arterial Hypertension: The SUPER-2 Study. 2012 , 2012, 124-125		1
213	Impact of first-line sildenafil monotherapy for pulmonary arterial hypertension. 2012 , 76, 1245-52		12
212	Selective PDE inhibitors as novel treatments for respiratory diseases. 2012 , 12, 275-86		116
211	WHO Group 1 pulmonary arterial hypertension: current and investigative therapies. 2012 , 55, 89-103		18
210	The pharmacological treatment of pulmonary arterial hypertension. 2012 , 64, 583-620		88
209	Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study. 2012 , 60, 768-74		101
208	Transition of PH patients from sildenafil to tadalafil: feasibility and practical considerations. 2012 , 190, 573-8		13

207	Pulmonary hypertension-"state of the art" management in 2012. 2012 , 64, 60-73	2
206	Pharmacotherapy for pulmonary arterial hypertension. 2012 , 8, 385-402	
205	Endothelial actions of atrial and B-type natriuretic peptides. 2012 , 166, 522-31	75
204	Prognostic factors in severe pulmonary hypertension patients who need parenteral prostanoid therapy: the impact of late referral. 2012 , 31, 364-72	38
203	Baseline NT-proBNP correlates with change in 6-minute walk distance in patients with pulmonary arterial hypertension in the pivotal inhaled treprostinil study TRIUMPH-1. 2012 , 31, 811-6	16
202	Heart rate recovery predicts clinical worsening in patients with pulmonary arterial hypertension. 2012 , 185, 400-8	64
201	Perioperative anesthesiological management of patients with pulmonary hypertension. 2012 , 2012, 356982	30
200	Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment. 2013 , 9, 1193-205	19
199	Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension. 2013 , 15, 475-83	42
198	Pharmacotherapy of Pulmonary Hypertension. 2013 ,	2
197	An update on medical therapy for pulmonary arterial hypertension. 2013 , 15, 614-22	17
196	Hipertensiã arterial pulmonar. 2013 , 11, 2625-2633	
195	Pulmonary hypertension in bronchopulmonary dysplasia. 2013 , 37, 124-31	107
194	Pulmonary Vascular Disease. 2013 , 603-625	1
193	Beyond pulmonary hypertension: sildenafil for chronic lung disease of prematurity. 2013 , 48, iii-v	10
192	[Early diagnosis and therapy in pulmonary hypertension--aspects of a vision]. 2013 , 67, 376-87	0
191	Management of pulmonary arterial hypertension. 2013 , 19, 44-50	7
190	Current world literature. 2013 , 19, 65-73	

189	Impact of sildenafil on survival of patients with Eisenmenger syndrome. 2013 , 53, 611-8	20
188	Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow?. 2013 , 22, 217-26	55
187	The effect of sildenafil on retinopathy of prematurity in very preterm infants. 2013 , 33, 218-21	17
186	Sildenafil increases sympathetically mediated vascular tone in humans. 2013 , 26, 762-9	12
185	Efficacy of right ventricular free-wall longitudinal speckle-tracking strain for predicting long-term outcome in patients with pulmonary hypertension. 2013 , 77, 756-63	87
184	Vascular Pharmacology. 2013 , 75-93	1
183	Novel mechanisms of sildenafil in pulmonary hypertension involving cytokines/chemokines, MAP kinases and Akt. 2014 , 9, e104890	31
182	Nuevos agentes para el tratamiento de la hipertensi3n pulmonar. 2014 , 21, 399-408	
181	Investigation of mutual pharmacokinetic interactions between macitentan, a novel endothelin receptor antagonist, and sildenafil in healthy subjects. 2014 , 78, 1035-42	18
180	Sildenafil for the treatment of pulmonary hypertension in children. 2014 , 12, 1157-84	12
179	Pulmonary arterial hypertension in adults: novel drugs and catheter ablation techniques show promise? Systematic review on pharmacotherapy and interventional strategies. 2014 , 2014, 743868	8
178	Advances in therapeutic interventions for patients with pulmonary arterial hypertension. 2014 , 130, 2189-208	209
177	Take a deep breath: understanding pulmonary arterial hypertension. 2014 , 37, 188-98	
176	Reducing TRPC1 Expression through Liposome-Mediated siRNA Delivery Markedly Attenuates Hypoxia-Induced Pulmonary Arterial Hypertension in a Murine Model. 2014 , 2014, 316214	16
175	The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases. 2014 , 2014, 257-90	10
174	Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension. 2014 , 33, 689-97	14
173	Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients. 2014 , 172, 332-9	34
172	Efficacy and safety of sildenafil treatment in pulmonary arterial hypertension: a systematic review. 2014 , 108, 531-7	29

171	STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension. 2014 , 129, 1914-23	129
170	Regression of pulmonary artery hypertension due to development of a pulmonary arteriovenous malformation. 2014 , 66, 535-8	2
169	New pharmacotherapies for pulmonary hypertension: where do they fit in?. 2014 , 16, 496	3
168	[Pulmonary hypertension--diagnostic and current concepts]. 2014 , 156, 49-52; quiz 53	
167	Current and advancing treatments for pulmonary arterial hypertension in childhood. 2014 , 8, 615-28	2
166	Current therapeutic approach in heart failure with preserved ejection fraction. 2014 , 10, 525-38	11
165	Upfront triple therapy for pulmonary arterial hypertension: is three a crowd or critical mass?. 2014 , 43, 1556-9	3
164	Long-term patient survival with idiopathic/heritable pulmonary arterial hypertension treated at a single center in Japan. 2014 , 118, 414-9	44
163	Riociguat: a novel therapeutic option for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. 2014 , 30, 1233-40	11
162	Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: efficacy and safety. 2014 , 13, 295-305	15
161	Polymorphism of the G protein β subunit gene influences the efficacy of sildenafil in patients with pulmonary hypertension. 2014 , 53, 291-7	9
160	Idiopathic pulmonary arterial hypertension in Asians: a long-term study on clinical outcomes. <i>Chest</i> , 2015 , 147, e160-e163	5-3 3
159	Endothelial cell regulation of pulmonary vascular tone, inflammation, and coagulation. 2015 , 5, 531-59	27
158	The limits of oral therapy in pulmonary arterial hypertension management. 2015 , 11, 1731-41	7
157	Physicochemical and Microbiological Stability of the Extemporaneous Sildenafil Citrate Oral Suspension. 2015 , 83, 659-70	1
156	Reported sildenafil side effects in pediatric pulmonary hypertension patients. 2015 , 3, 12	16
155	Safety and tolerability considerations in the use of sildenafil for children with pulmonary arterial hypertension. 2015 , 7, 175-83	5
154	[Medical treatment of pulmonary hypertension: what's new?]. 2015 , 56, 573-82	

153	Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study. 2015 , 15, 62	3
152	What is new about Rio?. 2015 , 45, 1211-3	1
151	Medikamentöse Therapie der pulmonal arteriellen Hypertonie. 2015 , 12, 390-400	
150	Erweiterungsstudie bestätigt Nutzen durch Guanylatcyclase-Stimulator. 2015 , 7, 30-30	
149	The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-study. 2015 , 47, 144-50	29
148	Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). 2015 , 45, 1303-13	131
147	Treatment of pulmonary arterial hypertension in children. 2015 , 12, 244-54	44
146	Pregnancy and pulmonary arterial hypertension: A clinical conundrum. 2015 , 5, 157-64	18
145	Use of outcome measures in pulmonary hypertension clinical trials. 2015 , 170, 419-29.e3	12
144	Macitentan reverses early obstructive pulmonary vasculopathy in rats: early intervention in overcoming the survivin-mediated resistance to apoptosis. 2015 , 308, L523-38	20
143	Role of sGC-dependent NO signalling and myocardial infarction risk. 2015 , 93, 383-94	22
142	Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension. 2015 , 193, 105-12	18
141	Sildenafil improves renal function in patients with pulmonary arterial hypertension. 2015 , 80, 235-41	13
140	Pulmonary Hypertension. 2015 , 192, 1514-6	5
139	Current Treatment Strategies, Guidelines and New Therapies. 2015 , 81-145	
138	New pharmacotherapy options for pulmonary arterial hypertension. 2015 , 16, 2113-31	17
137	Early decline in six-minute walk distance from the time of diagnosis predicts clinical worsening in pulmonary arterial hypertension. 2015 , 89, 365-73	6
136	Treatment of Pulmonary Hypertension. 2015 ,	1

135 Pulmonary Hypertension. **2015**, 179-197

134 [Therapy of Pulmonary Arterial Hypertension]. **2015**, 69, 483-93; quiz 494-5

133 Management of Heart Failure. **2015**,

1

132 Current treatment approaches to pulmonary arterial hypertension. **2015**, 31, 460-77

24

131 Vasculopathy and pulmonary hypertension in sickle cell disease. **2015**, 308, L314-24

90

130 Preventive effect of sildenafil on right ventricular function in rats with monocrotaline-induced pulmonary arterial hypertension. **2016**, 65, 215-22

6

129 Cyclic nucleotide phosphodiesterases in heart and vessels: A therapeutic perspective. **2016**, 109, 431-43

73

128 Evolution of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction in Taiwan. **2016**, 27, 66-70

7

127 Update on pulmonary arterial hypertension pharmacotherapy. **2016**, 128, 460-73

14

126 Right ventricular outflow tract assessment: Identification of right ventricle dysfunction in heart failure. **2016**, 68 Suppl 1, S5-7

125 Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. **2016**, 4, 361-71

69

124 Current and future direction in the management of scleroderma. **2016**, 308, 461-71

3

123 Anti-inflammatory Agents for the Prevention of Bronchopulmonary Dysplasia. **2016**, 325-344

1

122 Deletion of LR11 Attenuates Hypoxia-Induced Pulmonary Arterial Smooth Muscle Cell Proliferation With Medial Thickening in Mice. **2016**, 36, 1972-9

7

121 Non-invasive evaluation of pulmonary arterial blood flow and wall shear stress in pulmonary arterial hypertension with 3D phase contrast magnetic resonance imaging. **2016**, 5, 1071

23

120 A randomized double blinded placebo controlled trial of sildenafil for renoprotection prior to hilar clamping in patients undergoing robotic assisted laparoscopic partial nephrectomy. **2016**, 114, 785-788

4

119 [Targeted therapy of pulmonary arterial hypertension: Recommendations of the Cologne Consensus Conference 2016]. **2016**, 141, S33-S41

12

118 Rapid and high-dose titration of epoprostenol improves pulmonary hemodynamics and clinical outcomes in patients with idiopathic and heritable pulmonary arterial hypertension. *Journal of Cardiology*, **2016**, 68, 542-547

3

20

117	Prolonged vasodilatory response to nanoencapsulated sildenafil in pulmonary hypertension. 2016 , 12, 63-8	13
116	Medical therapies for pulmonary arterial hypertension. 2016 , 21, 273-83	7
115	Sildenafil reduces signs of oxidative stress in pulmonary arterial hypertension: Evaluation by fatty acid composition, level of hydroxynonenal and heart rate variability. 2016 , 7, 48-57	26
114	Bronchopulmonary Dysplasia. 2016 ,	3
113	Upfront combination therapy: does the AMBITION study herald a new era in the treatment of pulmonary arterial hypertension?. 2016 , 71, 107-9	5
112	The molecular targets of approved treatments for pulmonary arterial hypertension. 2016 , 71, 73-83	87
111	Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension. <i>Chest</i> , 2017 , 151, 468-480	57
110	Targeting the NO-sGC-cGMP Pathway in Pulmonary Arterial Hypertension. 2017 , 139-151	1
109	Pulmonary hypertension in connective tissue diseases: an update. 2017 , 20, 5-24	26
108	Identifying "super responders" in pulmonary arterial hypertension. 2017 , 7, 300-311	7
107	Epidemiology and treatment of pulmonary arterial hypertension. 2017 , 14, 603-614	182
106	Steps forward in the treatment of pulmonary arterial hypertension: latest developments and clinical opportunities. 2017 , 8, 47-64	19
105	Treatment initiation in paediatric pulmonary hypertension: insights from a multinational registry. 2017 , 27, 1123-1132	12
104	Diagnosis and Treatment of Pulmonary Hypertension. 2017 ,	0
103	Cardiac complications of systemic sclerosis and management: recent progress. 2017 , 29, 574-584	15
102	Estrategia terapèutica en hipertensi6 arterial pulmonar. 2017 , 24, 41-47	
101	Reynolds Syndrome: a rare rheumatologic disease that internists should have in mind. Case report. 2017 , 3,	
100	Sildenafil in the Treatment of Postoperative Hypoxemia with High Resistance in Cyanotic Congenital Heart Disease. 2017 , 13, 140-147	

99	Nitric oxide and pulmonary arterial hypertension. 2017 , 2017, 14	21
98	Effect of abnormal right heart structures on the diagnosis of pulmonary hypertension. 2018 , 8, 2045894018773053	3
97	Current Trends and Future Perspectives in the Treatment of Pulmonary Arterial Hypertension. 2018 , 43, 191-216	1
96	OBSOLETE: Pulmonary Hypertension. 2018 ,	
95	Sildenafil Use in the Treatment of Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension: A Case Series. 2018 , 8, e219-e222	3
94	Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018. 2018 , 272S, 37-45	33
93	Chronic Right Heart Failure: Expanding Prevalence and Challenges in Outpatient Management. 2018 , 14, 413-423	3
92	Dasatinib-Induced Pulmonary Arterial Hypertension Treated with Upfront Combination Therapy. 2018 , 2018, 3895197	3
91	Pulmonary Hypertension. 2018 , 204-222	
90	Pulmonary Arterial Hypertension: Pathophysiology and Treatment. 2018 , 6,	50
89	CHST3 and CHST13 polymorphisms as predictors of bosentan-induced liver toxicity in Japanese patients with pulmonary arterial hypertension. 2018 , 135, 259-264	4
88	Cardiac Physiology and Pharmacology. 2019 , 424-457.e17	1
87	Thyroid Dysfunction in Patients with Pulmonary Artery Hypertension (PAH): The Effect of Therapies Affecting the Prostanoid Pathway. 2019 , 197, 761-768	6
86	Pulmonary Arterial Hypertension and Therapeutic Interventions. 2019 , 28, 80-92	3
85	Towards improved pharmacotherapy in pulmonary arterial hypertension. Can diet play a role?. 2019 , 30, 159-169	2
84	Two Birds with One Stone: Regular Use of PDE5 Inhibitors for Treating Male Patients with Erectile Dysfunction and Cardiovascular Diseases. 2019 , 33, 119-128	10
83	Effect of a phosphodiesterase-5A (PDE5A) gene polymorphism on response to sildenafil therapy in canine pulmonary hypertension. 2019 , 9, 6899	6
82	Effects of home-based exercise training on functional outcomes and quality of life in patients with pulmonary hypertension: A randomized clinical trial. 2019 , 71, 161-165	16

81	Phosphodiesterase 5 inhibitors for pulmonary hypertension. 2019 , 1, CD012621	32
80	Sildenafil for Pulmonary Arterial Hypertension. <i>American Journal of Therapeutics</i> , 2019 , 26, e520-e526 1	19
79	Detection of Pediatric Pulmonary Arterial Hypertension by School Electrocardiography Mass Screening. 2019 , 199, 1397-1406	9
78	Pulmonary Hypertension. 2020 , 617-630.e3	
77	Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease. 2020 , 177, 5467-5488	34
76	The importance of the nitric oxide-cGMP pathway in age-related cardiovascular disease: Focus on phosphodiesterase-1 and soluble guanylate cyclase. 2020 , 127, 67-80	16
75	Niclosamide attenuates lung vascular remodeling in experimental pulmonary arterial hypertension. 2020 , 887, 173438	4
74	Persistent Pulmonary Hypertension of the Newborn: Pathophysiological Mechanisms and Novel Therapeutic Approaches. 2020 , 8, 342	12
73	Therapeutic Implications for PDE2 and cGMP/cAMP Mediated Crosstalk in Cardiovascular Diseases. 2020 , 21,	11
72	Efficacy and safety of Sildenafil treatment in pulmonary hypertension caused by chronic obstructive pulmonary disease: A meta-analysis. 2020 , 257, 118001	7
71	Newer approaches and novel drugs for inhalational therapy for pulmonary arterial hypertension. 2020 , 17, 439-461	11
70	Protective effects of intermedin/adrenomedullin-2 in a cellular model of human pulmonary arterial hypertension. 2020 , 126, 170267	4
69	Combined Methods (Formal Adjusted Indirect Comparison, Meta-Analysis and Principal Component Analysis) Comparisons of the Safety and Efficacy of Ambrisentan, Bosentan, and Sildenafil in the Patients With Pulmonary Arterial Hypertension. 2020 , 11, 400	5
68	Riociguat: Clinical research and evolving role in therapy. 2021 , 87, 2645-2662	7
67	Novel Insights Regarding Nitric Oxide and Cardiovascular Diseases. 2021 , 72, 411-425	7
66	Treating Moderate Aortic Stenosis: Too Early or Too Late?. 2021 , 23, 1	
65	In vivo Pharmacokinetics and in vitro Release of Imatinib Mesylate-Loaded Liposomes for Pulmonary Delivery. 2021 , 16, 1221-1229	3
64	Pulmonary Hypertension. 2021 , 174, ITC49-ITC64	7

63	A p97/Valosin-Containing Protein Inhibitor Drug CB-5083 Has a Potent but Reversible Off-Target Effect on Phosphodiesterase-6. 2021 , 378, 31-41	4
62	Systematic review and cost-effectiveness of bosentan and sildenafil as therapeutic drugs for pediatric pulmonary arterial hypertension. 2021 , 56, 2250-2258	1
61	Repurposing of the PDE5 Inhibitor Sildenafil for the Treatment of Persistent Pulmonary Hypertension in Neonates. 2021 , 28, 2418-2437	2
60	Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. 2021 , 9, 573-584	22
59	Haemodynamic effects of riociguat in CTEPH and PAH: a 10-year observational study. 2021 , 7,	2
58	Clinical Efficacy and Safety of Different Doses of Sildenafil in the Treatment of Persistent Pulmonary Hypertension of the Newborn: A Network Meta-analysis. 2021 , 12, 697287	1
57	Novel Approaches to Drug Discovery in Interstitial Lung Disease. 2022 , 182-188	
56	Pathophysiology and Pharmacotherapy of Adult Congenital Heart Disease. 2015 , 1269-1291	1
55	Contemporary Pharmacotherapies Involving Nitric Oxide, Prostacyclin, and Endothelin Receptor Signaling Pathways. 2016 , 257-270	1
54	[Phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension]. 2015 , 85, 215-24	6
53	Pulmonary arterial hypertension specific therapy: The old and the new. <i>Pharmacology & Therapeutics</i> , 2020 , 214, 107576	13.9 16
52	PULMONARY ARTERIAL HYPERTENSION IN SYSTEMIC CONNECTIVE TISSUE DISEASES: THE CURRENT STATE OF THE PROBLEM. 2018 , 56, 474-485	3
51	Treatment Selection in Pulmonary Arterial Hypertension: Phosphodiesterase Type 5 Inhibitors versus Soluble Guanylate Cyclase Stimulator. 2018 , 13, 35-37	9
50	The Nitric Oxide Pathway in Pulmonary Arterial Hypertension: Pathomechanism, Biomarkers and Drug Targets. 2020 , 27, 7168-7188	10
49	Current and emerging therapeutic approaches to pulmonary hypertension. 2020 , 21, 163-179	20
48	Cardiac Effects of Phosphodiesterase-5 Inhibitors: Efficacy and Safety. 2021 , 1	1
47	Antihypertonika. 2012 , 403-424	
46	Antihypertonika. 2013 , 391-412	

- 45 Legochnaya arterial'naya gipertenziya: na puti ot ratsional'noy diagnostiki k vyboru effektivnoy lekarstvennoy terapii. **2013**, 10, 57-69 1
- 44 PHARMACOTHERAPY OF PULMONARY HYPERTENSION DURING PREGNANCY AND POSTPARTUM PERIOD. **2013**, 21, 129
- 43 Diagnosis and Treatment of Pulmonary Arterial Hypertension. **2014**, 1-33
- 42 Diagnosis and Treatment of Pulmonary Arterial Hypertension. **2015**, 4105-4133
- 41 [Survival in pulmonary arterial hypertension, associated with connective tissue diseases, treated by sildenafil: results of the prospective study]. **2015**, 87, 62-67
- 40 Antihypertonika. **2015**, 451-475
- 39 The Real World of Medical Treatment of Pulmonary Arterial Hypertension—Small Evidence, but Heavy Cornerstone— **2015**, 31, 157-183
- 38 We Obtain A Hemodynamic Near Normalization? Clues from Three Long-Term Survivors on Epoprostenol Treatment. **2015**, 2,
- 37 Antihypertonika. **2016**, 335-350
- 36 Whatever Happened to Oral Monotherapy?. **2017**, 15, 190-192
- 35 Antihypertonika. **2017**, 335-351
- 34 Quality of life in patients with idiopathic pulmonary hypertension: the first experience of trimetazidine. **2017**, 14, 57-64 1
- 33 Survival of patients with pulmonary arterial hypertension during therapy PAH-specific drugs. **2017**, 14, 58-64
- 32 Antihypertonika. **2018**, 385-400
- 31 II. Idiopathic/Heritable Pulmonary Arterial Hypertension. **2018**, 107, 208-213 2
- 30 The Innovations in Pulmonary Hypertension Pathophysiology and Treatment: What are our Options!. **2019**, 14, 189-203
- 29 Clinical Outcomes and Treatment Options in Patients With Pulmonary Hypertension Who Received Pulmonary Hypertension-Specific Drugs - Single-Center Case Series. **2019**, 1, 389-395 0
- 28 Should oral combination therapy be the standard of care for pulmonary arterial hypertension?. **2020**, 14, 341-343

27	Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension. <i>Advances in Therapy</i> , 2021 , 39, 796	4.1	4
26	Phosphodiesterase-5 inhibitors. 2013 , 218, 229-55		2
25	Therapy for Pulmonary Arterial Hypertension: Glance on Nitric Oxide Pathway. 2021 , 12, 767002		4
24	A Semi-Automated Term Harmonization Pipeline Applied to Pulmonary Arterial Hypertension Clinical Trials. <i>Methods of Information in Medicine</i> , 2021 ,	1.5	
23	Hipertens arterial pulmonar no lpus eritematoso sistmico experincia do Centro de Atendimento Multiprofissional da Santa Casa de Misericrdia de So Paulo. <i>Revista Paulista De Reumatologia</i> , 2014 , 28-34	0.1	
22	New Therapeutic Targets in Neonatal Pulmonary Hypertension. 2022 , 1, 158-169		
21	Long-term mortality after pulmonary artery denervation stratified by baseline functional class in patients with pulmonary arterial hypertension: Long-term mortality after PADN stratified by functional class.. <i>AsiaIntervention</i> , 2022 , 8, 58-68	0.1	0
20	Therapeutic approaches to improve pulmonary arterial load and right ventricular pulmonary arterial coupling. 2022 , 935-958		
19	Drug Therapy for Unexplained Dyspnea in Post-COVID-19 Fatigue Syndrome: Empagliflozin and Sildenafil.. <i>American Journal of Therapeutics</i> , 2022 ,	1	1
18	DataSheet_1.docx. 2020 ,		
17	The treatment strategy of connective tissue disease associated pulmonary arterial hypertension: Evolving into the future.. <i>Pharmacology & Therapeutics</i> , 2022 , 108192	13.9	1
16	Outcome of mean pulmonary arterial pressure-based intensive treatment for patients with pulmonary arterial hypertension.. <i>Journal of Cardiology</i> , 2022 ,	3	1
15	Comprehensive review on novel targets and emerging therapeutic modalities for pulmonary arterial Hypertension.. <i>International Journal of Pharmaceutics</i> , 2022 , 621, 121792	6.5	1
14	Role of NO-cGMP-PKG axis in pulmonary arterial hypertension. <i>Folia Pharmacologica Japonica</i> , 2022 , 157, 221-225	0	
13	Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension. <i>Advances in Therapy</i> ,	4.1	
12	APPLICATION OF PHOSPHODIESTERASE TYPE 5 INHIBITORS SILDENAFIL IN PATIENTS WITH PULMONARY HYPERTENSION. 2015 , 42-49		2
11	Medications for the treatment of pulmonary arterial hypertension: a systematic review and network meta-analysis. 2022 , 31, 220036		1
10	Pulmonary Hypertension in Scleroderma Evaluation and Management. 2022 , 101468		0

9	Beyond Erectile Dysfunction: cGMP-Specific Phosphodiesterase 5 Inhibitors for Other Clinical Disorders. 2023 , 63,	1
8	Strategizing Drug Therapies in Pulmonary Hypertension for Improved Outcomes. 2022 , 15, 1242	2
7	Recent Advances in the Treatment of Pulmonary Arterial Hypertension. 2022 , 15, 1277	3
6	Comparison of intravenous sildenafil with inhaled nitric oxide for acute vasodilator testing in pulmonary arterial hypertension. 2022 , 12,	0
5	Pulmonary Hypertension.	0
4	Effect of Phosphodiesterase-5 (PDE-5) Inhibitors on Clinical Outcomes in Patients With Pulmonary Hypertension: A Meta-Analysis of Randomized Control Trials. 2023 ,	0
3	β adrenergic agonism: A novel pathway which improves right ventricular-pulmonary arterial hemodynamics in pulmonary arterial hypertension. 2023 , 11,	0
2	Egln1Tie2Cre Mice Exhibit Similar Therapeutic Responses to Sildenafil, Ambrisentan, and Treprostinil as Pulmonary Arterial Hypertension (PAH) Patients, Supporting Egln1Tie2Cre Mice as a Useful PAH Model. 2023 , 24, 2391	0
1	Advances in the discovery of drugs that treat pulmonary arterial hypertension. 2023 , 18, 445-466	0